Ambee Pharmaceuticals Ltd. announced unaudited earnings results for the third quarter and nine months ended March 31, 2017. EPS was BDT 0.92 for January-March, 2017 as against BDT 0.57 for January-March, 2016. EPS was BDT 2.32 for July, 2016-March, 2017 as against BDT 2.56 for July, 2015-March, 2016. NOCFPS was BDT 8.33 for July, 2016-March, 2017 as against BDT 5.89 for July, 2015-March, 2016. NAV per share was BDT 24.54 as of March 31, 2017 and BDT 24.82 as of June 30, 2016.